Drug Type Small molecule drug |
Synonyms Compound MR3(Guizhou University) |
Target |
Action degraders |
Mechanism ESR1 degraders(Estrogen receptor alpha degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC50H48N4O5S2 |
InChIKeyXNCXGLUWWRIIJQ-OZCIJLEVSA-N |
CAS Registry3070968-56-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | China | 11 Apr 2025 |